CLINICAL TRIALS PROFILE FOR ERTAPENEM SODIUM
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Ertapenem Sodium
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT00090272 ↗ | A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2002-04-01 | The objective of this study is to evaluate the safety and efficacy of a one time dose of an intravenous marketed drug being evaluated for a new indication as compared to a marketed drug already approved for the prevention of surgical site infection following colorectal surgery. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Ertapenem Sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00090272 ↗ | A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2002-04-01 | The objective of this study is to evaluate the safety and efficacy of a one time dose of an intravenous marketed drug being evaluated for a new indication as compared to a marketed drug already approved for the prevention of surgical site infection following colorectal surgery. |
| NCT00092170 ↗ | An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2002-03-01 | The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections. |
| NCT00379951 ↗ | A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-06-01 | The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults. |
| NCT00379964 ↗ | A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-06-01 | The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ertapenem Sodium
Condition Name
Clinical Trial Locations for Ertapenem Sodium
Trials by Country
Clinical Trial Progress for Ertapenem Sodium
Clinical Trial Phase
Clinical Trial Sponsors for Ertapenem Sodium
Sponsor Name
